Ziopharm Oncology Inc (NASDAQ:ZIOP) Sellers Reduced Their Shorts By 0.68%

Ziopharm Oncology Inc (NASDAQ:ZIOP) had a decrease of its shares shorted by 0.68%. FINRA issued in December ZIOP’s total 37.54M shares shorted. The down change of 0.68% from 37.80 million shares was reported. With Average volume 813,200, ZIOP’s former position will take 46 days to recover. Ziopharm Oncology Inc float short is 29%.

ZIOP touched $3.12 during the last trading session after $0.13 change.ZIOPHARM Oncology, Inc. is downtrending after having declined 54.20% since December 8, 2017. ZIOP has 1.89M volume or 12.11% up from normal. ZIOP underperformed the S&P 500 by 69.82%.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is worth $440.59 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Last it reported negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Total analysts of 2 have positions in ZIOPHARM Oncology (NASDAQ:ZIOP) as follows: 1 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 50%. Since June 18, 2018 according to StockzIntelligence Inc ZIOPHARM Oncology has 2 analyst reports. On Monday, June 18 the rating was downgraded by JP Morgan to “Underweight”. On Thursday, November 15 the company was upgraded by Raymond James.

For more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news published recently go to: Benzinga.com, Seekingalpha.com, Seekingalpha.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “35 Stocks Moving In Friday’s Mid-Day Session – Benzinga” published on November 23, 2018, “Ziopharm +1.6% after enrolling first patient in glioblastoma study – Seeking Alpha” on June 28, 2018, “Key events next week – healthcare – Seeking Alpha” with a publish date: November 09, 2018, “68 Stocks Moving In Friday’s Mid-Day Session – Benzinga” and the last “Ziopharm Oncology Is An Attractive Buy For 2018 – Seeking Alpha” with publication date: September 01, 2018.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.